共 50 条
Updated Review on Clinically-Relevant Properties of Delafloxacin
被引:6
|作者:
Turban, Adrien
[1
]
Guerin, Francois
[1
,2
]
Dinh, Aurelien
[3
]
Cattoir, Vincent
[1
,2
]
机构:
[1] Univ Hosp Rennes, Dept Bacteriol, 2 Rue Henri Le Guilloux, F-35000 Rennes, France
[2] Univ Rennes, Inserm, UMR S 1230 BRM, 2 Ave Pr Leon Bernard, F-35000 Rennes, France
[3] Versailles St Quentin Univ, Univ Hosp Raymond Poincare, AP HP, Infect Dis Dept,Paris Saclay, F-92380 Garches, France
来源:
ANTIBIOTICS-BASEL
|
2023年
/
12卷
/
08期
关键词:
fluoroquinolones;
levofloxacin;
moxifloxacin;
resistance;
topoisomerases;
ABSSSI;
CAP;
ACUTE BACTERIAL SKIN;
IN-VITRO ACTIVITY;
STAPHYLOCOCCUS-AUREUS;
TOPOISOMERASE-IV;
STREPTOCOCCUS-PNEUMONIAE;
STRUCTURE INFECTIONS;
DNA GYRASE;
QUINOLONE ACTION;
DOUBLE-BLIND;
PHASE-III;
D O I:
10.3390/antibiotics12081241
中图分类号:
R51 [传染病];
学科分类号:
100401 ;
摘要:
The extensive use of fluoroquinolones has been consequently accompanied by the emergence of bacterial resistance, which triggers the necessity to discover new compounds. Delafloxacin is a brand-new anionic non-zwitterionic fluoroquinolone with some structural particularities that give it attractive proprieties: high activity under acidic conditions, greater in vitro activity against Gram-positive bacteria-even those showing resistance to currently-used fluoroquinolones-and nearly equivalent affinity for both type-II topoisomerases (i.e., DNA gyrase and topoisomerase IV). During phases II and III clinical trials, delafloxacin showed non-inferiority compared to standard-of-care therapy in the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, which resulted in its approval in 2017 by the Food and Drug Administration for indications. Thanks to its overall good tolerance, its broad-spectrum in vitro activity, and its ease of use, it could represent a promising molecule for the treatment of bacterial infections.
引用
收藏
页数:23
相关论文